Lenvervimab
Based on 1 Customer Validation
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : ≥99%
- No. CAS: 2055006-79-4
- Peso molecular:147.526 kDa
-
Almacenamiento:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
HBV
In Vitro
Lenvervimab (1 nM-1 μM, 16 h) inhibits HBV infection in HepG2-NTCP cells infected with HBV[1].
Lenvervimab recognizes many viral genotypes and clinical variants of HBV infection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2-NTCP cells infected with HBV
-
Concentration:1 nM-1 μM
-
Incubation Time:16 h
-
Result:Inhibited viral expression of the surface antigen HBsAg (hepatitis B virus surface antigen) and the core protein HBcAg.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Aplicación
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 2055006-79-4
-
Appearance Liquid
-
Peso molecular 147.526 kDa
-
Color Colorless to light yellow
-
SMILES
[Lenvervimab]
-
Synonyms
GC1102
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Jeong GU, et al. A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants. PLoS One. 2020 Aug 13;15(8):e0236704. [Content Brief]
[2]. Lee HW, et al. Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2020 Dec;18(13):3043-3045.e1. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)